A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.

A phase I study to determine the maximum tolerated dose and toxicity of gemcitabine when given as a 24 h infusion to patients with inoperable non-small-cell lung cancer (NSCLC). A total of 24 patients with unresectable stage IIIa-IV NSCLC were entered into the study. Gemcitabine was administered as...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, H., Thatcher, N., Walling, J., Hansen, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074628/
https://www.ncbi.nlm.nih.gov/pubmed/8695365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074628/
https://www.ncbi.nlm.nih.gov/pubmed/8695365

Ejemplares similares